Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellowship Clinical Neurophysiology, Pediatrics/Duke University School Of Medicine, Duke University School of Medicine 2016 - 2017
  • Pediatric Neurology Fellowship, Pediatrics, University of Kentucky, Lexington 2013 - 2016
  • Chief Resident, Pediatrics, New York Medical College 2012 - 2013
  • Residency, Pediatrics, Maimonides Medical Center 2009 - 2012
  • M.B.B.S., King Edward Medical University (Pakistan) 2005
• 

  Medical Licensure

  • 2016-01267 . North Carolina. 2020
• 

  Duke Appointment History

  • Assistant Professor of Pediatrics, Pediatrics, Neurology, Pediatrics 2017 - 2020
• 

  Leadership & Clinical Positions at Duke

  • Director, Pediatrics Epilepsy Monitoring Unit
    Co- Director Tuberous sclerosis clinic
    
    
• Expertise
• 

  Subject Headings

  • Epilepsy
• Research
• 

  Selected Grants

  • LivaNova Core Registry awarded by LivaNova 2019 - 2026
  • Hartwell Individual Biomedical Research Award awarded by Hartwell Foundation 2021 - 2024
  • 1042-TSC-2001 - Marinus TSC awarded by Marinus Pharmaceuticals, Inc. 2020 - 2023
  • An open-label, long-term safety and tolerability study of b1ivaracetam as adjunctive treatment in pediatric study participants with epilepsy awarded by UCB Biopharma 2021 - 2023
  • Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome awarded by SK Life Science, Inc 2019 - 2022
  • OPEN-LABEL, SINGLE-ARM, MULTICENTER, LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN PEDIATRIC SUBJECTS WITH EPILEPSY awarded by UCB Pharma, Inc. 2018 - 2022
  • Study of Oral Pyridoxal 5'-Phosphate for the Treatment of Patients with PNPO Deficiency awarded by Medicure, Inc. 2021 - 2022
  • An Observational Study to Investigate Cognition and Quality of Life in Children and Adolescents with Dravet Syndrome (Pro00102865) awarded by Stoke Therapeutics, Inc. 2019 - 2022
  • A double-blind, randomized, placebo-controlled trial of adjunctive ganaxolone treatment in female children with protocadherin 19 (PCDH19)-related epilepsy followed by long-term open-label treatment awarded by Marinus Pharmaceuticals, Inc. 2019 - 2022
  • A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients awarded by Bio-Pharm Solutions Co., Ltd. 2020 - 2021
  • Phase I, Open-Label Study of Carisbamate in Adult and Pediatric Subjects with Lennox-Gastaut Syndrome awarded by SK Life Science, Inc 2020 - 2021
  • E2007-G000-238 Perampanel for <2 yrs awarded by Eisai, Inc. 2019 - 2021
  • A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS WITH EPILEPSY >1 MONTH TO <4 YEARS OF AGE WITH PARTIAL-ONSET SEIZURES awarded by UCB Biosciences Inc. 2019 - 2021
  • A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN PEDIATRIC SUBJECTS WITH EPILEPSY WITH PARTIAL-ONSET SEIZURES PHASE 3 awarded by UCB Biosciences Inc. 2019 - 2020
  • A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS BRIVARACETAM IN SUBJECTS ¿1 MONTH TO <16 YEARS OF AGE WITH EPILEPSY PHASE 2 awarded by UCB Pharma, Inc. 2018 - 2020
  • Microburst VNS Therapy Feasibility Study in Subjects with Refractory Epilepsy awarded by LivaNova 2019 - 2020
  • A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone Treatment in Children and Young Adults with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) Followed by Long-term Open-label Treatment awarded by Marinus Pharmaceuticals, Inc. 2018 - 2020
  • A Two-Part Study of ZX008 in Children and Adults with Lennox-Gastaut Syndrome (LGS) awarded by Zogenix International Limited 2019 - 2020
  • A Retrospective Multicenter Study to Investigate Dosage, Efficacy,and Safety of Fycompa® in Routine Clinical Care of Patients With Epilepsy awarded by Eisai, Inc. 2018 - 2019
• 

  External Relationships

  • LivaNova, Inc.

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.